Table 2.
Comparison of clinical variables between patients who showed deterioration of renal function during zoldronic acid therapy and patients who changed to denosumab due to other causes
| Variables | Deteriorated renal function | Other causes | Probability |
|---|---|---|---|
| Creatinine clearance rate at denosumab induction (ml/min) | 40.9 (33.3–55.0) | 75.4 (61.4–103.0)a | <0.0001 |
| Age (years) | 74.6 (71.4–79.2)a | 68.3 (64.1–75.1)a | 0.007 |
| Male/female (cases) | 23/3 | 27/4 | 0.772 |
| Disease (cases) renal cell cancer/urothelial cancer/prostate cancer | 9/3/14 | 7/1/23 | 0.336 |
| Creatinine clearance rate at zoledonic acid induction (ml/min) | 59.5 (45.3–73.5)a | 78.2 (58.3–93.3)a | 0.016 |
| Number of zoledronic acid administrations | 17.5 (15–27.5)a | 14 (6.3–32.3)a | 0.980 |
aNumbers represent median (inter-quartile range)